Votrient and Bone marrow failure - a phase IV clinical study of FDA data

Summary:

Bone marrow failure is reported as a side effect among people who take Votrient (pazopanib hydrochloride), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Yondelis, and have Renal cell carcinoma.

The phase IV clinical study analyzes which people have Bone marrow failure when taking Votrient. It is created by eHealthMe based on reports of 25,299 people who have side effects when taking Votrient from the FDA, and is updated regularly.

What is Votrient?

Votrient has active ingredients of pazopanib hydrochloride. It is often used in metastatic renal cell carcinoma. eHealthMe is studying from 25,347 Votrient users. Check the latest studies of Votrient.

What is Bone marrow failure?

Bone marrow failure is found to be associated with 1,015 drugs and 1,438 conditions by eHealthMe. Check the latest studies of Bone marrow failure.

On Jul, 11, 2026

25,299 people reported to have side effects when taking Votrient.
Among them, 41 people (0.16%) have Bone marrow failure.

Could Votrient cause Bone marrow failure?

Among these 41 people:

How long have people been on Votrient when they have Bone marrow failure? *

What is the gender of people who have Bone marrow failure when taking Votrient? *

female: 56 %
male: 44 %

What is the age of people who have Bone marrow failure when taking Votrient? *

What are other drugs people take besides Votrient? *

What are other side effects people have besides Bone marrow failure? *

Thrombocytopenia (decrease of platelets in blood): 13 people, 31.71%
Diarrhea: 8 people, 19.51%
Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 6 people, 14.63%
White Blood Cell Count Decreased: 5 people, 12.20%
High Blood Pressure: 5 people, 12.20%
Malaise (a feeling of general discomfort or uneasiness): 5 people, 12.20%
Nausea (feeling of having an urge to vomit): 4 people, 9.76%
Pneumonia: 4 people, 9.76%
Neutrophil Count Decreased (less than normal number of neutrophil a type of blood cell): 3 people, 7.32%
Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection): 3 people, 7.32%

What are the existing conditions these people have? *

Renal Cell Carcinoma (a kidney cancer): 20 people, 48.78%
Rhabdomyosarcoma (cancer of the bone, soft tissues, or connective tissue (e.g., tendon or cartilage)): 6 people, 14.63%
Liposarcoma (a cancer tumour that arises in fat cells in deep soft tissue): 3 people, 7.32%
Leiomyosarcoma (a very rare soft tissue sarcoma (cancer) that grows in muscle tissue): 3 people, 7.32%
Undifferentiated Sarcoma (undifferentiated cancer): 2 people, 4.88%
Synovial Sarcoma (tumour of synovial membrane of joint): 1 person, 2.44%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 1 person, 2.44%
Neuralgia (pain in one or more nerves): 1 person, 2.44%
Metastases To Bone (cancer spreads to bone): 1 person, 2.44%
Insomnia (sleeplessness): 1 person, 2.44%

* Approximation only. Some reports may have incomplete information.

Do you take Votrient and have Bone marrow failure?

- Check whether Bone marrow failure is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Votrient:

Votrient (25,347 reports)

Browse all side effects of Votrient:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Bone marrow failure:

Bone marrow failure (1,015 drugs)

Browse all the conditions that are associated with Bone marrow failure:

Bone marrow failure (1,438 conditions)

Related publications that referenced our studies

Costa DA, de Almeida SB, Barata PC, Quintela A, Cabral P, Afonso A, Silva JM, "Pazopanib-Induced Cutaneous Leukocytoclastic Vasculitis: An Exclusion Diagnosis of a Multidisciplinary Approach", Case Reports in Oncology, 2013 Jan .
Costa DA, de Almeida SB, Barata PC, Quintela A, Cabral P, Afonso A, Silva JM, "Pazopanib-Induced Cutaneous Leukocytoclastic Vasculitis: An Exclusion Diagnosis of a Multidisciplinary Approach", Case Reports in Oncology, 2013 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on pazopanib hydrochloride (the active ingredients of Votrient) and Votrient (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.